In comparison to IDH‐wildtype gliomas of the same grade, IDH‐mutant gliomas are associated with a rather favorable prognosis [10], and they occur in ~ 80% of WHO grade II/III gliomas [11]. This evidence concerns the gene IDH1 and central nervous system cancer.